GlaxoSmithKline signs deal with JT

GlaxoSmithKline (GSK) has signed an agreement with Japan Tobacco to develop a new cancer-based drug.

The pharmaceutical giant has inked a licensing agreement which will see GSK granted exclusive worldwide rights to manufacture a product targeting MARK/ERK kinase (MEK) inhibition.

Together the two firms will explore the drug’s medical application in preventing the growth of cancer cells and evaluate its commercial prospects. JT will market the drug in Japan if successful and will be entitled to further royalties if the drug takes off.

The Japanese firm says the drug is now under preclinical study in Japan, with its impact on the protein kinase MEK being determined.

MEK is an enzyme which is a key part of cell proliferation, with the potential for interfering in this process leading to wider uses in cancer and also inflammation. Inhibitors such as the drug JT and GSK will work on are able to block MEK.

© Adfero Ltd